-transparent.png){kind=logo}
OBJECTIVE Gastrointestinal effects are common adverse effects associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Lornoxicam is a new nonsteroidal anti-inflammatory drug and its gastroduodenal tolerability was compared to that of naproxen in a randomized, double-blind, crossover study. METHODS Eighteen healthy male volunteers received lornoxicam 8 mg b.d. or naproxen 500 mg b.d. administered orally over two 7-day dosing periods. Upper endoscopy was performed by two independent investigators at the beginning and end of each dosing regimen. RESULTS Lornoxicam 8 mg b.d. caused significantly less mucosal injury than naproxen 500 mg b.d. in the stomach/duodenal bulb, as well as in the mid/distal duodenum. CONCLUSIONS These findings may have favourable implications for lornoxicam in the clinical setting, if this dose provides optimal control of arthritic pain.
L Aabakken, and
M Osnes, and
W Frenzel
January 2003,
Inflammopharmacology,
L Aabakken, and
M Osnes, and
W Frenzel
June 2010,
Clinical therapeutics,
L Aabakken, and
M Osnes, and
W Frenzel
January 1998,
Drug metabolism and drug interactions,
L Aabakken, and
M Osnes, and
W Frenzel
August 2000,
The Journal of rheumatology,
L Aabakken, and
M Osnes, and
W Frenzel
January 2019,
Current therapeutic research, clinical and experimental,
L Aabakken, and
M Osnes, and
W Frenzel
April 1999,
British journal of clinical pharmacology,
L Aabakken, and
M Osnes, and
W Frenzel
April 2007,
British journal of clinical pharmacology,
L Aabakken, and
M Osnes, and
W Frenzel
April 2004,
The American journal of gastroenterology,
L Aabakken, and
M Osnes, and
W Frenzel
February 1992,
Clinical pharmacokinetics,
L Aabakken, and
M Osnes, and
W Frenzel
May 2024,
Clinical drug investigation,
